LL-PLS 1st in Ai search --- searched for:
monoclonal antibodies fcrn fetal compartment
This came up:
AI Overview
Monoclonal antibodies (mAbs) that target the neonatal Fc receptor (FcRn) can be used to treat and prevent fetal and neonatal diseases:
FcRn-enhancing mutations
These mutations can improve the delivery of therapeutic mAbs to the fetus. For example, leronlimab-PLS is a stabilized and FcRn-enhanced form of leronlimab that can reach higher levels in the fetus and newborn circulation.
Nipocalimab
This mAb is being studied as a treatment for hemolytic disease of the fetus and newborn (HDFN). It binds to FcRn with high affinity, reducing serum IgG levels and inhibiting the transfer of IgG across the placenta.
M281
This mAb can inhibit the transfer of IgG across the placenta, which may help treat fetal and neonatal diseases caused by pathogenic IgG antibodies.
Rozanolixizumab
This mAb inhibits FcRn and is being developed to treat IgG autoantibody-mediated diseases.
_______
* Nipocalimab:
Owned by J&J
https://www.jnj.com/media-center/press-releas...fcrn-class
*M281:
This is also Nipocalimab.
Johnson & Johnson
Myasthenia gravis focused.
https://adisinsight.springer.com/drugs/800045634
Nipocalimab missed primary in RA & this ---
" Serious adverse events were reported in three participants (burn infection, infusion-related reaction and deep vein thrombosis). Nipocalimab significantly and reversibly reduced serum immunoglobulin G, ACPA and circulating immune complex levels but not serum inflammatory markers, including CRP."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11227837/
*Rozanolixizumab:
Here's the Ai Overview.
It's kind of contradicting to knowingly being beneficial, via FcRn/placenta.
Rozanolixizumab is a monoclonal antibody that inhibits the neonatal Fc receptor (FcRn), which regulates the transfer of IgG antibodies across the placenta. Because of this, rozanolixizumab can reduce the amount of IgG antibodies that a mother passes on to her fetus. This could potentially reduce the amount of passive protection the newborn receives.
Animal studies:
In animal studies, rozanolixizumab treatment of pregnant dams resulted in offspring with very low levels of IgG at birth. However, the studies did not indicate any harmful effects on pregnancy, embryonic development, or postnatal development.
Limited data on human use:
There is limited data on the use of rozanolixizumab in pregnant women.
___________
Only looking @ these mentioned as FcRn based treatments.
The LL-PLS pub mentioned a couple follow-up things needed, but two other things from it:
"Over the past years, considerable efforts have been invested in optimizing monoclonal antibodies (mAbs) as preventative therapies against infections through the development of high-concentration formulations and engineering techniques that extend half-life and reduce the need for frequent dosing"
( Cytodyn's 2023 patent by Tracy, is based High Concentration Formula )
The 2nd publication point:
"This approach, aimed at improving mAb access to the fetal compartment, could facilitate the management of various emerging and established congenital diseases."
_____
Of course this is all new to me.
Reading on these viruses/disease FcRn drugs, notice they do not have the vast potential breath, of LL-PLS.
Let alone, LL-PLS's safety.
LL-PLS potential affects on medical industry & patients, is looking like could become immeasurable.
Placenta ---
no better starting point for CCR5 blockage.
monoclonal antibodies fcrn fetal compartment
This came up:
AI Overview
Monoclonal antibodies (mAbs) that target the neonatal Fc receptor (FcRn) can be used to treat and prevent fetal and neonatal diseases:
FcRn-enhancing mutations
These mutations can improve the delivery of therapeutic mAbs to the fetus. For example, leronlimab-PLS is a stabilized and FcRn-enhanced form of leronlimab that can reach higher levels in the fetus and newborn circulation.
Nipocalimab
This mAb is being studied as a treatment for hemolytic disease of the fetus and newborn (HDFN). It binds to FcRn with high affinity, reducing serum IgG levels and inhibiting the transfer of IgG across the placenta.
M281
This mAb can inhibit the transfer of IgG across the placenta, which may help treat fetal and neonatal diseases caused by pathogenic IgG antibodies.
Rozanolixizumab
This mAb inhibits FcRn and is being developed to treat IgG autoantibody-mediated diseases.
_______
* Nipocalimab:
Owned by J&J
https://www.jnj.com/media-center/press-releas...fcrn-class
*M281:
This is also Nipocalimab.
Johnson & Johnson
Myasthenia gravis focused.
https://adisinsight.springer.com/drugs/800045634
Nipocalimab missed primary in RA & this ---
" Serious adverse events were reported in three participants (burn infection, infusion-related reaction and deep vein thrombosis). Nipocalimab significantly and reversibly reduced serum immunoglobulin G, ACPA and circulating immune complex levels but not serum inflammatory markers, including CRP."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11227837/
*Rozanolixizumab:
Here's the Ai Overview.
It's kind of contradicting to knowingly being beneficial, via FcRn/placenta.
Rozanolixizumab is a monoclonal antibody that inhibits the neonatal Fc receptor (FcRn), which regulates the transfer of IgG antibodies across the placenta. Because of this, rozanolixizumab can reduce the amount of IgG antibodies that a mother passes on to her fetus. This could potentially reduce the amount of passive protection the newborn receives.
Animal studies:
In animal studies, rozanolixizumab treatment of pregnant dams resulted in offspring with very low levels of IgG at birth. However, the studies did not indicate any harmful effects on pregnancy, embryonic development, or postnatal development.
Limited data on human use:
There is limited data on the use of rozanolixizumab in pregnant women.
___________
Only looking @ these mentioned as FcRn based treatments.
The LL-PLS pub mentioned a couple follow-up things needed, but two other things from it:
"Over the past years, considerable efforts have been invested in optimizing monoclonal antibodies (mAbs) as preventative therapies against infections through the development of high-concentration formulations and engineering techniques that extend half-life and reduce the need for frequent dosing"
( Cytodyn's 2023 patent by Tracy, is based High Concentration Formula )
The 2nd publication point:
"This approach, aimed at improving mAb access to the fetal compartment, could facilitate the management of various emerging and established congenital diseases."
_____
Of course this is all new to me.
Reading on these viruses/disease FcRn drugs, notice they do not have the vast potential breath, of LL-PLS.
Let alone, LL-PLS's safety.
LL-PLS potential affects on medical industry & patients, is looking like could become immeasurable.
Placenta ---
no better starting point for CCR5 blockage.
5
